Study of how teclistamab works in multiple myeloma patients
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This study looks closely at patients’ immune cells to understand why teclistamab helps in multiple myeloma. Your participation could help doctors better predict who benefits and how the treatment works.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have multiple myeloma.
- You are receiving (or will receive) teclistamab as part of your care.
- You can sign a consent form to take part in the study.
- You are not under “legal protection” (a legal status that limits certain permissions).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how well two newer medicines, teclistamab and talquetamab, work in people with multiple myeloma that has come back or stopped responding to several treatments. If you qualify, you may be able to receive one of these medicines as part of your regular care.
This study tests whether giving the drug teclistamab (a treatment for multiple myeloma) in an outpatient setting is safe and works well. You may qualify if you have had at least three prior treatments, have a caregiver to support you, and meet other health criteria.
This Phase 2 study tests a study treatment in adults with multiple myeloma that needs treatment. It may help by trying to improve disease control after you’ve had (or are scheduled to have) standard therapy like chemotherapy and stem cell transplant for some people.
This trial tests a combination of two drugs—teclistamab (an immunotherapy) and mezigdomide (a targeted pill)—for people with multiple myeloma that has come back or not responded to previous treatments. The goal is to see if this new combination can help when other options have stopped working.
This Phase 2 trial tests two antibody medicines (teclistamab or talquetamab) given as outpatient injections, to treat multiple myeloma. It also tests preventing and treating side effects with supportive medicines, aiming to improve disease control in people who have already tried other myeloma treatments.
This trial tests a combination of two newer cancer-fighting drugs (teclistamab and daratumumab) to treat people who have just been diagnosed with multiple myeloma—a blood cancer—and also have light chain amyloidosis, a condition where abnormal proteins build up in organs. The goal is to see if this combination works better and is safe for newly diagnosed patients.
Hear when a new Multiple myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.